Technical Analysis for IMUX - Immunic, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Volume Surge | Other | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -0.40% | |
| MACD Bearish Signal Line Cross | Bearish | -0.40% | |
| Bollinger Band Squeeze | Range Contraction | -0.40% | |
| 50 DMA Resistance | Bearish | -3.86% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.86% | |
| 20 DMA Support | Bullish | -3.86% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 3 days ago |
| Possible Pocket Pivot | 3 days ago |
| Down 5% | 3 days ago |
| 5x Volume Pace | 3 days ago |
| Down 3% | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 06/11/2024
Immunic, Inc. Description
Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Clinical Development Autoimmune Disease Psoriasis Multiple Sclerosis Ulcerative Colitis Metabolism Ulcer Abdominal Pain Colitis Crohn's Disease Molecule Product Inflammatory And Autoimmune Diseases Mayo Clinic Primary Sclerosing Cholangitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.11 |
| 52 Week Low | 0.9451 |
| Average Volume | 341,501 |
| 200-Day Moving Average | 1.34 |
| 50-Day Moving Average | 1.30 |
| 20-Day Moving Average | 1.28 |
| 10-Day Moving Average | 1.28 |
| Average True Range | 0.08 |
| RSI (14) | 45.95 |
| ADX | 11.25 |
| +DI | 16.79 |
| -DI | 19.99 |
| Chandelier Exit (Long, 3 ATRs) | 1.19 |
| Chandelier Exit (Short, 3 ATRs) | 1.42 |
| Upper Bollinger Bands | 1.37 |
| Lower Bollinger Band | 1.18 |
| Percent B (%b) | 0.33 |
| BandWidth | 14.29 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0032 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.37 | ||||
| Resistance 3 (R3) | 1.36 | 1.31 | 1.35 | ||
| Resistance 2 (R2) | 1.31 | 1.28 | 1.31 | 1.34 | |
| Resistance 1 (R1) | 1.28 | 1.26 | 1.29 | 1.29 | 1.33 |
| Pivot Point | 1.23 | 1.23 | 1.24 | 1.23 | 1.23 |
| Support 1 (S1) | 1.20 | 1.20 | 1.21 | 1.21 | 1.16 |
| Support 2 (S2) | 1.15 | 1.18 | 1.15 | 1.15 | |
| Support 3 (S3) | 1.12 | 1.15 | 1.15 | ||
| Support 4 (S4) | 1.13 |
